Cardiothoracic & vascular anesthesia
Dexmedetomidine Sedation Combined With Remifentanil in MitraClip Procedures is Feasible and Improves Hemodynamics
Authors' conclusion
Dexmedetomidine/remifentanil sedation appears to be feasible and a safe option for MitraClip procedures, and provides better hemodynamic stability with faster emergence times compared with general anesthesia.
Study context
- Population
- Patients undergoing MitraClip procedures, single tertiary university centre, 2018–2020
- Participants
- 79 patients
- Exposure
- Dexmedetomidine/remifentanil conscious sedation vs general anesthesia (GA)
- Dexmedetomidine/remifentanil conscious sedation (DCS)n = 26
- GAn = 53reference
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Respiratory parameters: no differences between groups
Observational data: associations, not effects.
Further findings
MAP during procedure
Norepinephrine dose
Emergence to readiness for ICU transfer
Total process time
Total process time
- Comparable between groups
Safety
- Switch from DCS to GA (oral bleeding or prolonged procedure time) · both excluded from the analysis — DCS
- 2 events
Switch to open surgery; postoperative complications
- No switch to open surgery
- No differences in postoperative complications between DCS and GA
Original publication
Dexmedetomidine Sedation Combined With Remifentanil in MitraClip Procedures is Feasible and Improves Hemodynamics. J Cardiothorac Vasc Anesth. Published 9 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →